zygacine | 2777-79-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: zygacine
• 英文别名: [(1S,2S,6S,9S,10S,11R,12R,13S,14S,15S,18S,19S,22S,23S,25R)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] acetate
• CAS: 2777-79-9
• 化学式: C₂₉H₄₅NO₈
• 分子量: 535.678
• InChiKey: IGDRXLIXNAWBBF-JRLIYKMQSA-N

物化性质

• 沸点：
  655.9±55.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  38
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  140
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  sodium ethanolate 、 zygacine 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Shimizu; Hayashi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 79 <959> 615, 618

  摘要：

  DOI：

文献信息

• Regulators of the hedgehog pathway, compositions and uses related thereto
  申请人：Beachy A. Philip

  公开号：US20060128639A1

  公开（公告）日：2006-06-15

  The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.

  本发明提供了调节平滑蛋白依赖性通路激活的方法和试剂等。在某些实施例中，这些方法可用于对抗由于刺猬增强功能、ptc失去功能或平滑蛋白增强功能突变引起的刺猬通路不必要激活的表型效应。
• Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
  申请人：Fondazione Telethon

  公开号：EP2123306A1

  公开（公告）日：2009-11-25

  The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).

  本发明涉及使用干扰刺猬信号通路的化合物来制造预防、抑制和/或逆转与眼部新生血管相关的眼部疾病的药物。部分上述疾病是（湿性）老年性黄斑变性、（增殖性）糖尿病视网膜病变、新生血管性青光眼、视网膜静脉闭塞或早产儿视网膜病变（ROP）。
• INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO
  申请人：——

  公开号：US20020006931A1

  公开（公告）日：2002-01-17

  The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein comprising contacting a cell sensitive to the hedgehog protein with a steroidal alkaloid, or other small molecule, in a sufficient amount to reduce the sensitivity of the cell to the hedgehog protein.

  本发明提供了抑制由刺猬蛋白产生的旁分泌和/或自分泌信号的检测方法和试剂，包括将对刺猬蛋白敏感的细胞与类固醇生物碱或其他小分子接触，接触量足以降低细胞对刺猬蛋白的敏感性。
• Hedgehog antagonists, methods and uses related thereto
  申请人：——

  公开号：US20040060568A1

  公开（公告）日：2004-04-01

  The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.

  本申请涉及通过抑制刺猬通路（例如，使用刺猬通路拮抗剂，如本文所公开的拮抗剂）来抑制血管生成和治疗或预防不需要的细胞增殖（包括肿瘤）的组合物和方法。
• Inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer
  申请人：Thomson Andreas Axel

  公开号：US20060094660A1

  公开（公告）日：2006-05-04

  A method of protecting a patient from possible adverse effects of a treatment involving inhibition of the SHH-signalling pathway in the patient, the method comprising suppressing testosterone or its effect in the patient. A method of treating a proliferative disease such as cancer in a patient the method comprising inhibiting the SHH-signalling pathway and suppressing testosterone or its effect in the patient. Typically, the SHH-signalling pathway is inhibited using cyclopamine or a derivative thereof, and testosterone is suppressed using any one or more of a GnRH antagonist, a GnRH agonist, an androgen antagonist or a Sa-reductase inhibitor.

  一种保护患者免受涉及抑制患者体内SHH信号通路的治疗可能产生的不良反应的方法，该方法包括抑制患者体内的睾酮或其作用。一种治疗患者增殖性疾病（如癌症）的方法，该方法包括抑制患者体内的 SHH 信号通路和抑制睾酮或其作用。通常情况下，SHH-信号通路用环丙胺或其衍生物来抑制，睾酮用GnRH拮抗剂、GnRH激动剂、雄激素拮抗剂或Sa-还原酶抑制剂中的一种或多种来抑制。